Bottom line
XLV vs ETHSX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 63% by weight.
XLV is cheaper at 0.08% vs 1.18% — a difference of $110 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +5.3% for ETHSX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
XLV vs ETHSX side by side
| XLV | ETHSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 1.18% |
| Annual cost per $10k | $8 | $118 |
| 10-yr cost on $10k (prospectus) | $103 | $1,911 |
| Max front load | None | 5.25% |
| 12b-1 fee | 0.02% | 0.25% |
| 1-yr return | +14.5% | −1.9% |
| 5-yr return (annualized) | +8.1% | +5.3% |
| 10-yr return (annualized) | +9.8% | +6.4% |
| Best quarter | +14.5% | +14.2% |
| Worst quarter | −12.7% | −12.1% |
| Net assets (fund) | $40.6B | $757.9M |
| Number of holdings | 65 | 42 |
| Portfolio turnover | 2% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | ETHSX | Difference |
|---|---|---|---|
| 2024 | +2.5% | +3.5% | −1.0% |
| 2023 | +2.0% | +5.7% | −3.7% |
| 2022 | −2.1% | −9.4% | +7.4% |
| 2021 | +25.9% | +22.1% | +3.9% |
| 2020 | +13.3% | +13.0% | +0.2% |
| 2019 | +20.7% | +26.0% | −5.3% |
| 2018 | +6.3% | +6.0% | +0.3% |
| 2017 | +21.7% | +16.2% | +5.5% |
| 2016 | −2.8% | −14.9% | +12.1% |
Source: Fund prospectus bar charts
Holdings overlap
14 of XLV's top 25 holdings also appear in ETHSX's top 25.
| Holding | XLV | ETHSX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 12.47% |
| Johnson & Johnson | 10.64% | 6.45% |
| AbbVie Inc | 7.74% | 6.46% |
| UnitedHealth Group Inc | 6.57% | 5.49% |
| Merck & Co Inc | 5.52% | 5.08% |
| Thermo Fisher Scientific Inc | 3.24% | 2.79% |
| Abbott Laboratories | 2.75% | 1.65% |
| Gilead Sciences Inc | 2.73% | 3.34% |
| Intuitive Surgical Inc | 2.45% | 2.72% |
| Vertex Pharmaceuticals Inc | 2.19% | 3.38% |
| Bristol-Myers Squibb Co | 2.05% | 4.25% |
| Stryker Corp | 1.89% | 2.21% |
| Medtronic PLC | 1.75% | 1.80% |
| Boston Scientific Corp | 1.10% | 2.18% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between XLV and ETHSX?
Which is cheaper, XLV or ETHSX?
Should I own both XLV and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.